Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a pioneering biotechnology firm headquartered in the United States, focuses on developing innovative therapies for serious medical conditions. Founded in 2000, the company has made significant strides in the fields of regenerative medicine and cell therapy, particularly in the treatment of cardiovascular diseases and Duchenne muscular dystrophy (DMD).
Capricor's flagship product, CAP-1002, is a unique allogeneic cardiosphere-derived cell therapy that aims to improve heart function in patients with advanced heart failure. The company has garnered attention for its robust clinical trial results and commitment to advancing therapeutic options in underserved patient populations. With a strong market position and a dedication to scientific excellence, Capricor Therapeutics continues to lead the way in transforming the landscape of regenerative medicine.
-20 vs industry average
Capricor Therapeutics, Inc.’s score of 18 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Capricor Therapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Capricor Therapeutics, Inc. yet.
Capricor Therapeutics, Inc.'s reported carbon emissions
Capricor Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards.
Given the lack of emissions data and reduction initiatives, it is unclear how Capricor Therapeutics is addressing climate change or its carbon footprint. The absence of a climate pledge or specific targets suggests that the company may still be in the early stages of developing a comprehensive sustainability strategy. As the industry increasingly prioritises environmental responsibility, it will be essential for Capricor Therapeutics to consider implementing measurable climate commitments in the future.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Capricor Therapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Capricor Therapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Capricor Therapeutics, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project